Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17- demethoxygeldanamycinin pediatric patients with recurrent or refractory solid tumors: A pediatric oncology experimental therapeutics investigators consortium study

Clinical Cancer Research

Volumn 13, Issue 6, 2007, Pages 1783-1788

  Bagatell, Rochelle ^a,n   Gore, Lia ^b   Egorin, Merrill J ^c   Ho, Richard ^d   Heller, Glenn ^e   Boucher, Nichole ^e   Zuhowski, Eleanor G ^a   Whitlock, James A ^d   Hunger, Stephen P ^f   Narendran, Aru ^g   Katzenstein, Howard M ^h   Arceci, Robert J ⁱ   Boklan, Jessica ^j   Herzog, Cynthia E ^k   Whitesell, Luke ^l   Ivy, S Percy ^m   Trippett, Tanya M ^e  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF FLORIDA   (United States)

^g UNIVERSITY OF CALGARY   (Canada)

^h CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

^j PHOENIX CHILDREN'S HOSPITAL   (United States)

^k UNIVERSITY OF TEXAS   (United States)

^l WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^m NATIONAL CANCER INSTITUTE   (United States)

ⁿ UNIVERSITY OF ARIZONA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; MACROCYCLIC LACTAM; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPIRATION; BILIRUBIN BLOOD LEVEL; BRADYCARDIA; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DESMOPLASTIC SMALL ROUND CELL TUMOR; DIARRHEA; DISEASE COURSE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; EWING SARCOMA; FEMALE; HUMAN; HYPOXIA; LEUKOPENIA; LUNG METASTASIS; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROBLASTOMA; NEUTROPENIA; OSTEOSARCOMA; PAROXYSMAL COUGHING; PEDIATRICS; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY ACIDOSIS; RESPIRATORY TRACT ALLERGY; RHABDOMYOSARCOMA; SIDE EFFECT; TACHYCARDIA; THROMBOCYTOPENIA; TRANSAMINITIS; NEOPLASM; PATHOLOGY; PRESCHOOL CHILD; RECURRENT DISEASE; TREATMENT FAILURE;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BENZOQUINONES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LACTAMS, MACROCYCLIC; MALE; MAXIMUM TOLERATED DOSE; NEOPLASMS; PEDIATRICS; RECURRENCE; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 34250162501     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1892     Document Type: Article

References (33)

1. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
2. Schnur RC, Corman ML, Gallaschun RJ, et al. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J Med Chem 1995;38:3806-12.
3. Schulte TW, Blagosklonny MV, Romanova L, et al. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Mol Cell Biol 1996;16:5839-45.
4. Segnitz B, Gehring U. The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin. J Biol Chem 1997;272:18694-701.
5. Smith DF, Whitesell L, Nair SC, Chen S, Prapapanich V, Rimerman RA. Progesterone receptor structure and function altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 1995;15:6804-12.
6. Bagatell R, Beliakoff J, David CL, Marron MT, Whitesell L. Hsp90 inhibitors deplete key antiapoptotic proteinsi n pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. Int J Cancer 2005;113:179-88.
7. Whitesell L, Sutphin P, An WG, Schulte T, Blagosklonny MV, Neckers L. Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo. Oncogene 1997;14:2809-16.
8. Whitesell L, Sutphin PD, Pulcini EJ, Martinez JD, Cook PH. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 1998;18:1517-24.
9. Forsythe HL, Jarvis JL, Turner JW, Elmore LW, Holt SE. Stable association of hsp90 and p23, but not hsp70, with active human telomerase. J Biol Chem 2001;276:15571-4.
10. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitorsof Hsp90 function. J Biol Chem 2002;277:39858-66.
11. Minami Y, Kiyoi H, Yamamoto Y, et al. Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cellsby Hsp90 inhibitors. Leukemia 2002;16:1535-40.
12. Stepanova L, Leng X, Parker SB, Harper JW. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev 1996;10:1491-502.
13. Mesa RA, Loegering D, Powell HL, et al. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cellsto cytarabine. Blood 2005;106:318-27.
14. Nimmanapalli R, O'Bryan E, Bhalla K. Geldanamycin and its analogue17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 2001;61:1799-804.
15. Yang ZF, Ho DW, Lam CT, et al. Identification of brain-derived neurotrophic factor as a novel functional protein in hepatocellular carcinoma. Cancer Res 2005;65:219-25.
16. Kim S, Kang J, Hu W, Evers BM, Chung DH. Geldanamycin decreases Raf-1 and Akt levels and induces apoptosis in neuroblastomas. Int J Cancer 2003;103:352-9.
17. Lopez-Maderuelo MD, Fernandez-Renart M, Moratilla C, Renart J. Opposite effects of the Hsp90 inhibitor geldanamycin: induction of apoptosis in PC12, and differentiation in N2A cells. FEBS Lett 2001;490:23-7.
18. Whitesell L, Shifrin SD, Schwab G, Neckers LM. Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. Cancer Res 1992;52:1721-8.
19. Grem JL, Morrison G, Guo X-D, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005;23:1885-93.
20. Goetz MP, Toft D, Reid J, et al. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23:1078-87.
21. Ramanathan RK, Trump DL, Eiseman JL, et al. Phase I pharmacokinetic- pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 2005;11:3385-91.
22. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152-61.
23. Ramanathan RK, Belani CP, Friedland D, et al. Phase I study (twice weekly schedule) of 17-allylamino-17 demethoxygeldanamycin (17AAG, NSC-704057) in patients with advanced refractory tumors. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings. Vol 23, No 16S: 3050.
24. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelinesto evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
25. Egorin MJ, Rosen DM, Wolff JH, Callery P, Musser SM, Eiseman JL. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 1998;58:2385-96.
26. Yeh KC, Kwan KC. A comparison of numerical integrating algorithmsby trapezoidal, Lagrange, and spline approximation. J Pharmacokinet Biopharm 1978;6:79-98.
27. Rocci ML, Jr., Jusko WJ. LAGRAN programfor area and moments in pharmacokinetic analysis. Comput Programs Biomed 1983;16:203-16.
28. Baker MK, Mikhitarian K, Osta W, et al. Molecular detection of breast cancer cells in the peripheral blood of advanced-stage breast cancer patients using multimarker real-time reverse transcription-polymerase chain reaction and a novel porous barrier density gradient centrifugation technology. Clin Cancer Res 2003;9:4865-71.
29. Picard D. Available from: http://www.picard.ch/downloads/ Hsp90interactors, updated 2006.
30. Kamal A, Boehm MF, Burrows FJ. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 2004;10:283-90.
31. Solit DB, Anana M, Valentin G, et al. Phase I trial of 17-AAG (17-allylamino-17-demethoxygeldanamycin) in patients with advanced cancer. J Clin Oncol, 2003 ASCO Annual Meeting Proceedings. Vol 22: 198.
32. Kamal A, Thao L, Sensintaffar J, et al. A high affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors. Nature 2003;425:407-10.
33. Mimnaugh EG, Xu W, Vos M , et al. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther 2004;3:551-66.